Mylan and Biocon’s biosimilar trastuzumab, which will be sold as Ogivri and which references Herceptin, today received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Mylan and Biocon’s biosimilar trastuzumab, which will be sold as Ogivri and which references Herceptin, today received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
“Obtaining a positive CHMP opinion for Ogivri is another significant achievement in Mylan’s continued efforts to bring more affordable medicines to the market,” said Mylan president Rajiv Malik. “The strong science and technology program behind this product has been instrumental in achieving this milestone and moving us one step closer to providing patients with this alternative option.”
The positive opinion is based on a package that includes analytical data as well as preclinical and clinical studies. The results from the studies found that there were no clinically meaningful differences in terms of quality, potency, and safety. Findings from the phase 3 Heritage clinical trial demonstrated that no clinically meaningful differences were present with respect to safety, efficacy, or immunogenicity when the biosimilar was compared with the reference.
Ogivri is indicated for the treatment of patients with human epidermal growth factor receptor 2—positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
The European Commission is expected to make a final decision regarding authorization by the end of 2018. Ogivri has already received regulatory approvals in 35 countries around the world, including the United States, where it earned FDA approval in 2017.
The product is not yet launched in the United States; while Mylan and Herceptin developer Roche reached a global settlement and license agreement in March 2017, it remains to be seen when the biosimilar will become available on the US market.
In looking to the future of the Mylan—Biocon partnership, Arun Chandavarkar, PhD, CEO and joint managing director of Biocon, said, “We shall continue to execute on our biosimilars strategy of expanding affordable access to high quality products targeting critical illnesses like cancer.”
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.